Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Change in Accured Expenses (2024 - 2025)

Prelude Therapeutics' Change in Accured Expenses history spans 2 years, with the latest figure at -$515000.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 132.87% year-over-year to -$515000.0; the TTM value through Dec 2025 reached -$3.0 million, down 268.81%, while the annual FY2025 figure was -$3.0 million, 268.81% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$515000.0 at Prelude Therapeutics, down from -$367000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.1 million in Q3 2024 and bottomed at -$5.7 million in Q1 2024.